How Oncologists Build a Personalised Cancer Treatment Plan

How Oncologists Build a Personalised Cancer Treatment Plan

No two tumours behave identically, even when they carry the same diagnosis on paper. That's the starting premise behind personalised treatment planning, and it's why two patients with what looks like the same cancer can walk out of consultations with entirely different regimens.

Building that plan is less a single decision than a sequence of them, each narrowing the options based on new information about the tumour, the patient's body, and how the two are likely to respond together.

Reading the Tumour Before Deciding Anything

The process begins with characterising the cancer itself: its type, grade, stage, and increasingly its genetic and molecular profile. Biopsy tissue is now routinely tested for specific mutations that can predict whether a targeted drug or immunotherapy is likely to work, information that simply didn't exist in most treatment plans a decade ago.

This is where Dr James Wilson, consultant oncologist, and specialists like him spend considerable time before recommending anything concrete, since a plan built on incomplete tumour data risks either overtreating a manageable cancer or undertreating an aggressive one.

The Multidisciplinary Team Behind the Recommendation

Personalised planning rarely comes from one clinician working alone. A multidisciplinary team, typically including a medical oncologist, surgeon, radiologist, pathologist and radiation oncologist, reviews the case together and debates the options before a recommendation reaches the patient.

Research on multidisciplinary team meetings has found this collaborative structure genuinely changes outcomes, not just documentation, by catching details a single specialist working in isolation might miss.

The tradeoff is speed. Coordinating five or six specialists' calendars takes longer than a single consultant issuing a decision, which is one reason private clinics with tighter internal scheduling can sometimes turn a recommendation around faster than larger public hospital departments.

Matching Treatment to the Whole Patient, Not Just the Tumour

A tumour that responds well to an aggressive chemotherapy regimen on paper isn't automatically the right target for that regimen in a specific patient. Age, kidney and liver function, existing heart conditions, and even a patient's own stated priorities around fertility or quality of life all shape what actually gets prescribed.

This is where personalisation moves from theoretical to practical. Two patients with identical tumour genetics might receive different plans because one has well-controlled diabetes and wants to keep working through treatment, while the other has limited kidney reserve that rules out certain drug classes entirely.

Age alone changes calculations in ways that surprise many patients. A regimen considered standard for a 45-year-old might be dose-adjusted or substituted entirely for a 78-year-old, not because the cancer is different but because the body metabolising the drug is. Oncologists increasingly use formal frailty assessments rather than age alone to make this call, since chronological age turns out to be a poor predictor of how well someone tolerates aggressive treatment.

Building in Flexibility From the Start

A personalised plan isn't static. Most oncologists build in scan checkpoints every few cycles specifically to catch early signs that a treatment isn't working, so the plan can pivot before months are lost to an ineffective regimen.

Patients sometimes assume switching treatment mid-course signals failure. In practice it's closer to the opposite: a plan designed with review points built in is doing exactly what it was designed to do when it adapts to new scan data.

Genetic testing itself sometimes evolves mid-treatment too. Tumours can develop new mutations under the selective pressure of a drug that was initially working, which is part of why some plans include repeat biopsies or blood-based tumour DNA tests partway through a course rather than relying entirely on the original tissue sample months later.

Where Patients Fit Into the Decision

The final step in most modern treatment planning is a conversation, not a prescription handed down. Patients are increasingly asked to weigh in on trade-offs between, for example, a more intensive regimen with a marginally better statistical outcome versus a gentler one that preserves quality of life during a limited remaining timeframe.

That shift towards shared decision-making has been slow but consistent across oncology generally, and it's arguably the most meaningful part of what makes a treatment plan feel personalised rather than merely tailored to biology.

Cost also enters these conversations more openly than it once did, particularly for patients weighing a newer targeted therapy against a well-established generic regimen with a similar statistical outcome. Being told honestly that two options carry a similar survival benefit but a very different price tag is, for many patients, more useful information than a purely clinical comparison.

Ultimately, a personalised plan is only as good as the honesty built into the conversation that produced it. Patients who ask direct questions about why a specific drug, dose or sequence was chosen tend to end up with plans that fit them better than those who accept a recommendation without probing the reasoning behind it, simply because the questions surface details the consultant might not have volunteered unprompted.